Dapagliflozin delivers cardiometabolic benefits in patients with myocardial infarction, regardless of their baseline A1c ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

The researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio ...

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

During follow-up, the primary outcome occurred in 16.4% of participants in the dapagliflozin group and 19.5% of participants in the placebo group, for an HR of 0.82 (95% CI, 0.73-0.92; P < .001).

Dapagliflozin might reduce the risk for ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection fraction (HFrEF), a post hoc analysis of the DAPA-HF trial ...